| Literature DB >> 17355644 |
Natasha Anne Lannin1, Lindy Clemson, Annie McCluskey, Chung-Wei Christine Lin, Ian D Cameron, Sarah Barras.
Abstract
BACKGROUND: Pre-discharge home visits aim to maximise independence in the community. These visits involve assessment of a person in their own home prior to discharge from hospital, typically by an occupational therapist. The therapist may provide equipment, adapt the home environment and/or provide education. The aims of this study were to investigate the feasibility of a randomised controlled trial in a clinical setting and the effect of pre-discharge home visits on functional performance in older people undergoing rehabilitation.Entities:
Mesh:
Year: 2007 PMID: 17355644 PMCID: PMC1832184 DOI: 10.1186/1472-6963-7-42
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Figure 1Flow of participants through the trial.
Baseline Characteristics of Participants
| Control Group (n = 5) | Intervention Group (n = 5) | |
| Age (years) | 82.4 (7) | 80.0 (7) |
| Gender: number of women (%) | 3 (60%) | 5 (100%) |
| Marital status: number of married (%) | 1 (20%) | 0 (0%) |
| Living situation: number living alone (%) | 4 (80%) | 4 (80%) |
| Length of Rehabilitation Stay in days (mean (SD)) | 25.4 (15) | 25 (18) |
| Length of Acute Hospital Stay (prior to Rehabilitation) in days (mean (SD)) | 12.5 (5) | 7 (3) |
| Home Ownership: number who owned their house (%) | 4 (80%) | 3 (60%) |
| Blaylock's Discharge Planning Risk Assessment Screen Score: score 0–40 | 10 (4) | 9.8 (3) |
| Short Portable Mental Status Questionnaire number of errors (mean (SD)) | 1 (1) | 0.8 (1) |
| Home Services: number receiving (%) | ||
| Cleaning | 3 (60%) | 1 (20%) |
| Grocery Assistance | 3 (60%) | 0 (0%) |
| Gardening/Outdoor maintenance | 1 (20%) | 0 (0%) |
| Reasons for admission: number (%) | ||
| Fall (without fracture) | 3 (60%) | 1 (10%) |
| Joint Replacement | 1 (20%) | 4 (80%) |
| Other | 1 (20%) | 0 (0%) |
Outcome scores and estimates of effects of all outcome measures for the control group and experimental group.
| OUTCOME SCORE | ANCOVA-ADJUSTED ESTIMATES OF EFFECTS* | p-value | |||
| Outcome Measure | Control | Experimental | |||
| Functional Independence Measure: total score (sd), 0–126 | 2 weeks | 115.2 (± 6.3) | 117.7 (± 3.3) | 2.5 (-6.7 to 11.9) | .525 |
| 1 month | 116.5 (± 7.4) | 117.7 (± 3.9) | 1.3 (-10.6 to 13.27) | .788 | |
| 2 months | 112.2 (± 10.0) | 120.0 (± 2.1) | 8.72 (-3.4 to 20.9) | .125 | |
| 3 months | 118.0 (± 4.0) | 115.7 (± 6.8) | -0.1 (-13.9 to 13.8) | .982 | |
| Reintegration to Normal Living Index: total score (sd), 0–100 | 2 weeks | 59.2 (± 20.3) | 63.0 (± 9.6) | 4.1 (-27.5 to 35.6) | .754 |
| 1 month | 56.7 (± 23.7) | 56.2 (± 15.8) | 0.8 (-34.8 to 36.5) | .953 | |
| 2 months | 53.2 (± 38.6) | 83.0 (± 9.5) | 30.5 (-39.7 to 100.8) | .294 | |
| 3 months | 83.6 (± 9.8) | 82.0 (± 8.2) | -1.7 (-22.8 to 19.4) | .835 | |
| Nottingham Extended Activities of Daily Living scale: total score (sd), 0–66 | 2 weeks | 37.2 (± 10.9) | 45.7 (± 5.9) | 16.1 (4.9 to 27.1) | .012 |
| 1 month | 33.7 (± 20.1) | 46.7 (± 3.4) | 17.0 (-12.88 to 46.95) | .203 | |
| 2 months | 36.0 (± 13.9) | 51.7 (± 3.1) | 23.0 (12.2 to 33.8) | .003 | |
| 3 months | 43.3 (± 7.1) | 56.7 (± 2.2) | 17.6 (-3.2 to 38.5) | .079 | |
| Tinnetti Performance Oriented Mobility Scale: total score (sd) 0–28 | 2 weeks | 20.3 (± 2.9) | 20.0 (± 1.4) | 0.5 (-3.0 to 4.2) | .639 |
| 1 month | 22.0 (± 1.4) | 24.0 (± 6.9) | 2.2 (-8.9 to 13.2) | .639 | |
| 2 months | 17.0 (± 11.5) | 22.7 (± 2.7) | 2.7 (-13.9 to 19.3) | .694 | |
| 3 months | 23.0 (± 1.7) | 23.5 (± 1.7) | 0.5 (-3.8 to 4.8) | .779 | |
| Falls Efficacy Scale- International: total score (sd), 0–64 | 2 weeks | 33.6 (± 7.1) | 30.2 (± 8.9) | -2.3 (-18.1 to 13.5) | .735 |
| 1 month | 31.5 (± 8.0) | 28.5 (± 7.3) | -2.5 (-19.8 to 14.7) | .722 | |
| 2 months | 36.2 (± 9.5) | 23.2 (± 4.2) | -14.8 (-30.7 to 1.17) | .063 | |
| 3 months | 30.0 (± 3.0) | 22.2 (± 4.5) | -3.2 (-10.5 to 4.1) | .287 | |
| EQ-5D VAS: total score (sd), 0–100 | 2 weeks | 35.2 (± 30.8) | 69.2 (± 11.3) | 21.4 (-21.1 to 64.0) | .252 |
| 1 month | 62.25 (± 18.0) | 79.3 (± 10.1) | 8.6 (-21.4 to 38.8) | .470 | |
| 2 months | 48.3(± 32.4) | 87.0 (± 9.2) | 31.7 (-23.4 to 86.9) | .185 | |
| 3 months | 54.0 (± 25.0) | 85.0 (± 8.5) | 23.3 (-17.4 to 64.1) | .187 | |
* Between-group differences adjusted for the baseline value of the outcome Larger scores reflect decreased risk except for the FES-I